Dyp...as you have pointed to NIH and this recruiting tool, we haven't heard much out of the Alzheimer's Clinical Trials Consortium (ACTC) that the NIH was hoping to lead the way in Alzheimer's research. A little investigation into the NIH leads to not much progression in this touted Consortium. The two major initiatives are a collaboration with Biogen/Eisai on the BAN2401 P3 to reduce AB amyloid and a similar collaboration with Cognition Therapeutics on their drug, CT1812. Although CT1812 is a small molecule which targets the sigma-2 receptor, it is in early stages of clinical development to again stop AB accumulation. Such disappointment in this important NIH initiative.
----
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. has discovered and is developing a pipeline of novel, disease modifying, oral drug candidates to treat a broad array of neurodegenerative and neuro-ophthalmic disorders. Our pipeline compounds uniquely target the s-2 receptor, a key regulator of the cellular damage response. CT1812, our lead product candidate, is being assessed in a comprehensive clinical program for Alzheimer’s disease, including a 540-person Phase 2 study in collaboration with ACTC and supported by a competitive grant from the National Institute on Aging. Additional information about Cognition and its product candidates may be found online at www.cogrx.com.
News 
Market Data 
Discover 
